

<b>r-TEG value (normal range)</b>	<b>Definition</b>	<b>Interpretation</b>
<b>ACT (86-118 seconds)</b>	<b>Time from start of assay to initiation of clot</b>	<b>Prolonged with factor deficiency or severe hemodilution</b>
<b>r-value (0.0-1.0 minutes)</b>	<b>Time between beginning of assay and initial clot formation</b>	<b>Prolonged with factor deficiency or severe hemodilution</b>
<b>k-time (1.0-2.0 minutes)</b>	<b>Time needed to reach 20-mm clot strength</b>	<b>Increased with hypofibrinogenemia or platelet dysfunction</b>
<b>alpha-angle (66-82 degrees)</b>	<b>Rate or acceleration of clot formation</b>	<b>Decreased with hypofibrinogenemia or platelet dysfunction</b>
<b>mA (54-72 mm)</b>	<b>Contribution of platelet function and platelet-fibrin interactions</b>	<b>Decreased with platelet dysfunction and or hypofibrinogenemia</b>
<b>LY-30% (0-7.5%)</b>	<b>Amplitude reduction 30 minutes after achieving mA (degree of fibrinolysis)</b>	<b>Increased with accelerated fibrinolysis</b>

<b>ACT &gt; 128</b>	<b>Transfuse plasma</b>
<b>r-value &gt; 1.1</b>	<b>Transfuse plasma</b>
<b>k-time &gt; 2.5</b>	<b>Transfuse plasma Add cryoprecipitate/fibrinogen if angle also abnormal</b>
<b><math>\alpha</math>-angle &lt; 60</b>	<b>Transfuse cryoprecipitate (or fibrinogen) Add platelets if mA is also abnormal</b>
<b>MA &lt; 55</b>	<b>Transfuse platelets Add cryoprecipitate/fibrinogen if angle also abnormal</b>
<b>LY-30 &gt; 3%</b>	<b>Administer tranexamic acid or amino-caproic acid</b>